Qoliana is owned by Sandoz Inc.
Qoliana contains Brimonidine Tartrate.
Qoliana has a total of 1 drug patent out of which 0 drug patents have expired.
Qoliana was authorised for market use on 22 May, 2006.
Qoliana is available in solution/drops;ophthalmic dosage forms.
The generics of Qoliana are possible to be released after 19 August, 2025.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US7265117||SANDOZ INC||Topical brimonidine tartrate formulations that lack chlorine dioxide|| |
(2 years from now)
Market Authorisation Date: 22 May, 2006
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic